替尔泊肽在肥胖治疗中的应用价值与机遇

Application value and opportunity of Tirzepatide in treatment of obesity

摘要:

肥胖目前已成为全球性的重大公共卫生问题，不断增加的患病率及并发症给医疗保健系统带来巨大负担。目前被批准用于减重的药物相对较少。替尔泊肽为葡萄糖依赖性促胰岛素多肽（GIP）/胰高血糖素样肽-1（GLP-1）双受体激动剂，是一种治疗2型糖尿病（T2DM）的新型药物。相比传统的GLP-1受体激动剂，其具有更显著的降糖和减重疗效。该文阐述替尔泊肽减重的可能作用机制、临床研究数据等，探讨其用于肥胖治疗的可行性和安全性，为治疗肥胖提供一种新选择。

Abstract:

The prevalence of obesity is a major global public health threat. The increasing prevalence and concurrent diseases have imposed an enormous burden on the healthcare system. Relatively few drugs are currently approved for weight loss. Tirzepatide, known as a dual receptor agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), is a new drugs treatment for type 2 diabetes mellitus (T2DM). Compared with traditional GLP-1 receptor agonists. Tirzepatide has more significant effective for weight and glucose loss. In this review, we summarize the possible mechanism of Tirzepatide for weight loss, clinical research data, etc., and then discuss its feasibility and safety for obesity treatment, which could provide a new option for the treatment of obesity.